Show simple item record

dc.contributor.advisorGong, Haiyanen_US
dc.contributor.advisorOffner, Gwynneth D.en_US
dc.contributor.authorChang, Joshua Suaen_US
dc.date.accessioned2019-07-03T17:40:25Z
dc.date.available2019-07-03T17:40:25Z
dc.date.issued2019
dc.identifier.urihttps://hdl.handle.net/2144/36171
dc.description.abstractAmyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that affects between 14,000 to 15,000 Americans. The upper and lower motor neurons degenerate, which eventually causes muscle paralysis, atrophy, and ultimately death from respiratory failure. It has a high treatment cost as well as a high toll on the patient and their families and friends. Currently, there are only two drugs approved by the FDA for the treatment of ALS: riluzole and edaravone. Research is constantly being conducted to understand and develop further treatment modalities, however, many drugs have failed to demonstrate significant improvement in phase III trials. One of the pathophysiology that these drugs, including riluzole, target is excitotoxicity of the motor neurons. This review will briefly expand upon the different trials that were conducted targeting the excitotoxicity pathway. Although they may have not been successful in prolonging survival in ALS patients, we can learn from these studies and build upon them.en_US
dc.language.isoen_US
dc.subjectMedicineen_US
dc.subjectALSen_US
dc.subjectAmyotrophic lateral sclerosisen_US
dc.titleA review of therapeutics targeting excitotoxicity in amyotrophic lateral sclerosisen_US
dc.typeThesis/Dissertationen_US
dc.date.updated2019-06-11T01:01:48Z
etd.degree.nameMaster of Scienceen_US
etd.degree.levelmastersen_US
etd.degree.disciplineMedical Sciencesen_US
etd.degree.grantorBoston Universityen_US


This item appears in the following Collection(s)

Show simple item record